Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.

Neurology - 11 Sept 2018

Touat Mehdi, Gratieux Julie, Condette Auliac Stephanie, Sejean Karine, Aldea Sorin, Savatovsky Julien, Perkins Géraldine, Blons Hélène, Ligon Keith L, Idbaih Ahmed, Hollebecque Antoine, Gimenez-Roqueplo Anne-Paule, Laurent-Puig Pierre, Sanson Marc, Villa Chiara, Di Stefano Anna Luisa

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Azetidines
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Ganglioglioma

Share to Piperidines

Share to Proto-Oncogene Proteins B-raf

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 30120137
DOI: 10.1212/WNL.0000000000006171
PMCID: PMC9694795

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib and cobimetinib overcome resistance to vemurafenib in BRAF-mutant ganglioglioma.PMID 30120137Read ↗

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.Semantic proximity Read ↗

BRAF-MEK Inhibition Is Effective in BRAFV600E-Mutant Papillary Craniopharyngioma.Semantic proximity Read ↗

Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with BRAF p.T599dup mutation.Semantic proximity Read ↗

Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.Semantic proximity Read ↗

The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Semantic proximity Read ↗

A critical review of RAF inhibitors in BRAF-mutated glioma treatment.Semantic proximity Read ↗

Sustained Tumor Control With MAPK Inhibition in BRAF V600–Mutant Adult Glial and Glioneuronal TumorsSemantic proximity Read ↗

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumorsSemantic proximity Read ↗

Tovorafenib effective against low-grade gliomas harbouring BRAF fusions.Semantic proximity Read ↗

Rapid symptomatic improvement in two patients with ganglioglioma after restarting BRAF inhibitor therapy.Semantic proximity Read ↗

Cobimetinib and vemurafenib for the treatment of melanoma.Semantic proximity Read ↗

Dabrafenib and trametinib in BRAFV600E mutated glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.